Heidrun L. Deissler

Giessen, HE 35392, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.

Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

Published: November 25, 2025

Novel Needle for Intravitreal Injections Does Not Affect Biological Activity of Anti-VEGF Drugs.

Novel Needle for Intravitreal Injections Does Not Affect Biological Activity of Anti-VEGF Drugs.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: July 31, 2025

Faricimab Reverts VEGF-A165-Induced Impairment of the Barrier Formed by Retinal Endothelial Cells.

Faricimab Reverts VEGF-A165-Induced Impairment of the Barrier Formed by Retinal Endothelial Cells.

Journal: International journal of molecular sciences

Published: March 10, 2025

VEGF-A165a and angiopoietin-2 differently affect the barrier formed by retinal endothelial cells.

VEGF-A165a and angiopoietin-2 differently affect the barrier formed by retinal endothelial cells.

Journal: Experimental eye research

Published: April 09, 2024

Different responses of the MIO‑M1 Mueller cell line to angiotensin II under hyperglycemic or hypoxic conditions.

Different responses of the MIO‑M1 Mueller cell line to angiotensin II under hyperglycemic or hypoxic conditions.

Journal: Biomedical reports

Published: May 10, 2023

Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A165 No Longer Depends on the Growth Factor's Presence.

Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A165 No Longer Depends on the Growth Factor's Presence.

Journal: Biomolecules

Published: March 28, 2022

Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.

Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.

Journal: Scientific reports

Published: December 22, 2021

Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.

Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.

Journal: Experimental eye research

Published: September 07, 2021

Type of culture medium determines properties of cultivated retinal endothelial cells: induction of substantial phenotypic conversion by standard DMEM.

Type of culture medium determines properties of cultivated retinal endothelial cells: induction of substantial phenotypic conversion by standard DMEM.

Journal: Heliyon

Published: September 29, 2020

Transport and fate of aflibercept in VEGF-A165-challenged retinal endothelial cells.

Transport and fate of aflibercept in VEGF-A165-challenged retinal endothelial cells.

Journal: Experimental eye research

Published: March 23, 2020

Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.

Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.

Journal: Journal of diabetes research

Published: November 14, 2019

VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A165-induced disturbances of barriers formed by retinal endothelial cells or long-term cultivated ARPE-19 cells.

VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A165-induced disturbances of barriers formed by retinal endothelial cells or long-term cultivated ARPE-19 cells.

Journal: Experimental eye research

Published: October 01, 2019

Showing 1-12 of 30

Last Updated: 09/26/2026